A randomized, double-blind, placebo-controlled study of daily cannabidiol for the treatment of canine osteoarthritis pain.

Autor:	Verrico CD; Department of Psychiatry.; Department of Pharmacology, Baylor College of Medicine, Houston, TX, United States., Wesson S; Sunset Animal Hospital, Houston, TX, United States., Konduri V; Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX, United States., Hofferek CJ; Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX, United States., Vazquez-Perez J; Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX, United States., Blair E; Valimenta Labs, Fort Collins, CO, United States., Dunner K Jr; Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX, United States., Salimpour P; Boston University School of Medicine, Boston, MA, United States., Decker WK; Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX, United States.; Center for Cell and Gene Therapy.; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, United States., Halpert MM; Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX, United States.
Jazyk:	angličtina
Zdroj:	Pain [Pain] 2020 Sep 01; Vol. 161 (9), pp. 2191-2202.
DOI:	10.1097/j.pain.0000000000001896
Abstrakt:	Abstract: Over the last 2 decades, affirmative diagnoses of osteoarthritis (OA) in the United States have tripled due to increasing rates of obesity and an aging population. Hemp-derived cannabidiol (CBD) is the major nontetrahydrocannabinol component of cannabis and has been promoted as a potential treatment for a wide variety of disparate inflammatory conditions. Here, we evaluated CBD for its ability to modulate the production of proinflammatory cytokines in vitro and in murine models of induced inflammation and further validated the ability of a liposomal formulation to increase bioavailability in mice and in humans. Subsequently, the therapeutic potential of both naked and liposomally encapsulated CBD was explored in a 4-week, randomized placebo-controlled, double-blinded study in a spontaneous canine model of OA. In vitro and in mouse models, CBD significantly attenuated the production of proinflammatory cytokines IL-6 and TNF-α while elevating levels of anti-inflammatory IL-10. In the veterinary study, CBD significantly decreased pain and increased mobility in a dose-dependent fashion among animals with an affirmative diagnosis of OA. Liposomal CBD (20 mg/day) was as effective as the highest dose of nonliposomal CBD (50 mg/day) in improving clinical outcomes. Hematocrit, comprehensive metabolic profile, and clinical chemistry indicated no significant detrimental impact of CBD administration over the 4-week analysis period. This study supports the safety and therapeutic potential of hemp-derived CBD for relieving arthritic pain and suggests follow-up investigations in humans are warranted. (Copyright © 2020 International Association for the Study of Pain.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu